Telix Pharmaceuticals (ASX:TLX) and Regeneron Pharmaceuticals (NASDAQ:REGN) have announced a global collaboration to co-develop and co-commercialise next-generation radiopharmaceutical therapies.
The 50/50 cost and profit-sharing partnership aims to marry Telix’s established radiopharmaceutical development and manufacturing infrastructure with Regeneron’s world-class antibody discovery platforms, including its proprietary VelocImmune technology.
The agreement focuses on multiple solid tumour targets, leveraging Regeneron’s extensive portfolio of bispecific antibodies to create highly targeted therapies.
Beyond treatment, the collaboration extends to the development of companion radiodiagnostics designed to improve patient selection and monitor treatment response with greater accuracy.
Dr John Lin of Regeneron highlighted the synergy, noting that targeted radiopharmaceuticals represent a "rapidly emerging frontier" that complements their existing toolkit of monoclonal antibodies and cell therapies.
Financially, the deal provides Telix with an immediate US$40 million upfront payment for four initial therapeutic programmes.
Regeneron maintains the option to expand this to four additional programmes, potentially triggering further payments.
Telix stands to earn up to US$2.1 billion in aggregate development and commercial milestones, alongside low double-digit royalties.
Telix CEO Christian Behrenbruch emphasised that this alliance reflects a unique opportunity to explore the full potential of biologics-based radiopharmaceuticals for patients with hard-to-treat cancers.